COVID-19PANDORNCT04336956
Covid-19 Pediatric Observatory
An observational study of COVID-19, run by Centre Hospitalier Intercommunal Creteil at 76 sites in France.
Trial summary
In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei Province in the People's Republic of China. The disease spreads rapidly and the number of sick people is increasing. Read more about this study
- Who is it for?
- Ages 0 to 18 years
- Conditions the study is for
- COVID-19
- What is being tested?
- hospitalized children with Covid19
- How many people
- 5,000 participants
- Where
- 76 sitesFrance
- Study dates
- 7 Apr 2020to 30 Jun 2024
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: children hospitalized with covid19
Who may be able to join
- Children < 18 years old
- Admitted in French pediatric wards
- With a confirmed COVID-19 infection. ( on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
Who cannot join
- Expressed refusal to participate
Trial locations and contacts
76 sites in 1 country.
76 sites in 1 country
France76 sites, 76 recruiting
- Recruiting
Ch St Esprit
Agen
Marie Mizzi
- Recruiting
Ch General Aix En Provence -
Aix-en-Provence
Claire Charreton
- Recruiting
CHU Angers
Angers
Gerald Boussicault
Leboucher
- Recruiting
CH d'ANGOULEME
Angoulème
Sylvie Roullaud
- Recruiting
Pringy - Ch D'Annecy
Annecy
Chantal Peigne
- Recruiting
CH Argenteuil
Argenteuil
Philippe Bensaid, MD
- Recruiting
Ch Armentieres
Armentières
Sophie Enchery
- Recruiting
CH Arpajon
Arpajon
Ekaterina KUTSIA
- Recruiting
Ch Auxerre
Auxerre
Bertrand Soto
Mougenot
- Recruiting
CH GENERAL Henri Duffaut
Avignon
Charlotte Pons
- Recruiting
CHU de BESANCON
Besançon
Raphaël Anxionnat
- Recruiting
Hopital Femme Enfant
Caen
Jacques Brouard
Valentin
- Recruiting
Ch de Pontoise
Cergy-Pontoise
Blandine Robert
Mohamed-Amine Yangui
- Recruiting
Ch W. Morey
Chalon-sur-Saône
Sandrine Anne Martha
- Recruiting
CH de CHAMBERY
Chambéry
Charlène Dupré
- Recruiting
Ch Hotel Dieu
Chartres
Rémi Kom
- Recruiting
CHU Estaing
Clermont-Ferrand
Isabelle Petit
- Recruiting
Hopital Louis Pasteur
Colmar
Didier Chognot
Marie Szulc
- Recruiting
Hopital Louis Mourrier
Colombes
Danekova
- Recruiting
CH Sud Francilien
Corbeil-Essonnes
Sebastien Rouget
- Recruiting
Centre Hospitalier intercommunal de Creteil
Créteil, 94010
Camille Jung
Xavier DURRMEYER
- Recruiting
Ch de Dax
Dax
Claude Chenel
- Recruiting
Hopital D'Enfants Chu Dijon
Dijon
Frédéric Huet
Verney
- Recruiting
CH Louviers Val de Reuil
Elbeuf
Dana Dabbagh
- Recruiting
CH Jean Monnet
Épinal
Brigitte Auburtin
- Recruiting
CH Gonesse
Gonesse
Maryssa Sarakbi
- Recruiting
CH d'HYERES
Hyères
danielle Roybet
- Recruiting
Ch de Marne La Vallee
Jossigny
Nathalie Garrec
Videsheka MADPATHAGE SENANAYAKE
- Recruiting
Chru de Grenoble
La Tronche
Cécile Bost-Bru
Fruscione
- Recruiting
CHGénéral du HAVRE
Le Havre
Belgaid Abdelmalek
- Recruiting
Hopital Jeanne de Flandre
Lille
Stéphane Leteurtre
- Recruiting
Hopital Roger Salengro - Lille
Lille
François Dubos, MD
Alain Martinot
- Recruiting
Hopital Saint Vincent de Paul
Lille
Valentine Hoeusler
Nicolas Kalach
- Recruiting
Ch de Longjumeau
Longjumeau
Sarah Ducrocq
- Recruiting
Lorient - Ch de Bretagne Sud
Lorient
Camille Le Stradic, MD
- Recruiting
Hopital Femme Mere Enfant-Bron
Lyon
Manon Passard
Manon Passard
- Recruiting
Hopital de Mantes
Mantes-la-Jolie
Béatrice Pellegrino
- Recruiting
Hopital Nord Enfants
Marseille
Philippe Minodier
- Recruiting
Hopital de Meaux
Meaux
Olivier Vignaud
Fleury Marjory
- Recruiting
Ch de Melun
Meulin
Caroline Thach
- Recruiting
CH de Montargis
Montargis
Richard Gruss
- Recruiting
CH de MONTBRISON
Montbrison
Christine Roche
- Recruiting
Hopital Arnaud de Villeneuve
Montpellier
Lea Thevenet
- Recruiting
CHRU de Nancy
Nancy
Florent Girard
Cyril Schweitzer
- Recruiting
Nantes - Hopital Mere Enfant
Nantes
Anne Drouard
- Recruiting
Ch de Neuilly Sur Seine
Neuilly-sur-Seine
Mariana Marin
- Recruiting
Hopital Lenval
Nice
hervé Haas
- Recruiting
CHU Nimes Caremeau
Nîmes
Sophie Odorico, MD
- Recruiting
Chr Orleans
Orléans
Françoise Monceaux
Imen Jhaouat
- Recruiting
Assistance Publique Hôpitaux de Paris
Paris, 75004
François Angoulvant
François Angoulvant
- Recruiting
Hopital St Jean Roussillon
Perpignan
Paulin Meslin
- Recruiting
POISSY - CH de POISSY
Poissy
Philippe Blanc
- Recruiting
QUIMPER - CH de Cornouaille
Quimper
Camille Loeile
- Recruiting
RANG du FLIERS - C.H.A.M.
Rang-du-Fliers
Sylvie Louf
- Recruiting
Hopital Américain CHU REIMS
Reims
Elmerich Florence
- Recruiting
CH RODEZ
Rodez
Bernard Caurier
- Recruiting
CH de ROMANS
Romans-sur-Isère
Patricia Guglielmino
- Recruiting
Chu Rouen
Rouen
Nathalie Mestre
- Recruiting
Hopital Charles-Nicolle
Rouen
Didier Pinquier
- Recruiting
Chu Felix Guyon
Saint-Denis, La Réunion
Benjamin Azemar
- Recruiting
Ch de Saint Denis
Saint-Denis
Alexis Mandelcwajg, MD
- Recruiting
Chu St Etienne
Saint-Etienne
Aymeric Cantais
- Recruiting
Ch Du Pays Du Mont Blanc
Sallanches
Emmanuelle Dessioux
- Recruiting
Chg Salon de Provence
Salon-de-Provence
Eric Moulène
- Recruiting
Ch de Saint Malo
St-Malo
Jean-Marie Lepage
- Recruiting
CH Hautepierre
Strasbourg
Jeanne Bordet
Yvan De Feraudy
- Recruiting
CH Tarbes
Tarbes
Vanessa Latry, MD
- Recruiting
CH Bel Air
Thionville
Jean-Marc Schneider
- Recruiting
Hopital Sainte Musse
Toulon
Paul Casha
- Recruiting
CHU Toulouse-hôpital des Enfants
Toulouse
camille Brehin
- Recruiting
Hôpital Gatien De Clocheville
Tours
Zoha Maakaroun-Vermesse
Charlotte Idier
- Recruiting
Hôpital Nord Franche-Comté
Trévenans
Nicoleta Ursulescu
- Recruiting
CH de TROYES
Troyes
Brigitte zimmerman
Stéphane Sanchez
- Recruiting
Ch Bretagne Atlantique
Vannes
Cécilia Marques, MD
- Recruiting
Ch Le Chesnay
Versailles
Marie-Aliette Dommergue
Véronique Hentgen
- Recruiting
Hopital de Villeneuve Saint Georges
Villeneuve-Saint-Georges
Aurélie Garraffo, MD
About this study
In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei Province in the People's Republic of China. The disease spreads rapidly and the number of sick people is increasing. On January 3, 2020 a new virus of the coronavirus family is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhan and subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the World Health Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On 11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus 2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is a pandemic.
As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with more than 16,000 deaths attributed to this virus. (Ref WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ).
Read more
In France, the number of cases rose from 105 cases at the end of February to 19615 confirmed cases on March 24. (Source Public Health France). Most of the cases are adults. However, children are not completely spared and serious cases have been described. These severe cases can be respiratory or extra-respiratory (e.g. myocarditis). We also know that pediatric and adult cases differ in terms of clinical, biological and imaging findings, particularly chest CT scans. However, the description of paediatric pictures, especially severe forms and the involvement of children suffering from co-morbidities, remains poorly reported. Finally, the risk factors for serious cases in children remain largely unknown.
This observatory aim to describe the clinical phenotypes of hospitalized pediatric patients with Covid19 in France, according to age groups. Moreover for a subgroup of patients, informations regarding the long covid will be reported.
- Conditions
- COVID-19
- Being tested
- hospitalized children with Covid19
- Keywords
- children, pediatric department
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
hospitalized children with Covid19Other
All patients under 18 years hospitalized with a covid19 diagnosis
| Study group | Role | What they receive |
|---|---|---|
| hospitalized children with Covid19 | - Children < 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs Receives: Other: hospitalized children with Covid19 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of children with severe or critical form.
Measured: Day 14
Secondary outcomes (13)
Percentage of children requiring intensive care support
Measured: at admission
Percentage of children requiring intensive care support
Measured: at day 14
Clinical symptoms of children
requiring intensive care support or not
Measured: at admission
Clinical symptoms of children
requiring intensive care support or not
Measured: day 14
Biological results of children
requiring intensive care support or not
Measured: at admission
Biological results of children
requiring intensive care support or not
Measured: day 14
CT chest of children
requiring intensive care support or not
Measured: at admission
Pulmonary echography
requiring intensive care support or not
Measured: Day 14
nasopharynx SARScov2 PCR
Measured: at admission
nasopharynx sarscov2 load
if available
Measured: at day 7
nasopharynx multiplex PCR
if available
Measured: at admission
number of hospital days
days
Measured: up to 12months
Evaluation of long covid
Measured: up to 12months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2020
- Study start7 Apr 2020
- Primary completion30 Jun 2024 (estimated)
- Study completion30 Jun 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 5,000 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Intercommunal Creteil
- Sponsor type
- University, hospital or other
- Collaborators
- Association Clinique Thérapeutique Infantile du val de Marne, Groupe de Pathologies Infectieuses Pédiatriques (GPIP), Société Française de Pédiatrie, Francophone Pediatric Resuscitation and Emergency Group (GFRUP)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04336956
- Sponsor's protocol ID
- PANDOR
- Acronym
- PANDOR
- Status last verified
- Nov 2022
- First submitted
- 30 Mar 2020
- Last updated
- 25 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rybak A, Ouldali N, Werner A, Casha P, Robert B, de Pontual L, Bechet S, Cahn-Sellem F, Angoulvant F, Cohen R, Levy C; PANDOR study group. Characteristics of Children Hospitalized for Acute COVID-19 in France From February 2020 to December 2023. Pediatr Infect Dis J. 2025 Apr 1;44(4):346-350. doi: 10.1097/INF.0000000000004681. Epub 2025 Feb 14.
PubMed 39961110
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Covid-19 Pediatric Observatory
- ClinicalTrials.gov ID
- NCT04336956
- Acronym / sponsor ID
- PANDOR / PANDOR
- Conditions
- COVID-19
- Keywords
- children, pediatric department
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Centre Hospitalier Intercommunal CreteilUniversity, hospital or other
- Collaborators
- Association Clinique Thérapeutique Infantile du val de Marne, Groupe de Pathologies Infectieuses Pédiatriques (GPIP), Société Française de Pédiatrie, Francophone Pediatric Resuscitation and Emergency Group (GFRUP)
- Study start
- 7 Apr 2020 (actual)
- Primary completion
- 30 Jun 2024 (estimated)
- Study completion
- 30 Jun 2024 (estimated)
- First posted
- 7 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei Province in the People's Republic of China. The disease spreads rapidly and the number of sick people is increasing. On January 3, 2020 a new virus of the coronavirus family is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhan and subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the World Health Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On 11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus 2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is a pandemic.
As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with more than 16,000 deaths attributed to this virus. (Ref WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ).
In France, the number of cases rose from 105 cases at the end of February to 19615 confirmed cases on March 24. (Source Public Health France). Most of the cases are adults. However, children are not completely spared and serious cases have been described. These severe cases can be respiratory or extra-respiratory (e.g. myocarditis). We also know that pediatric and adult cases differ in terms of clinical, biological and imaging findings, particularly chest CT scans. However, the description of paediatric pictures, especially severe forms and the involvement of children suffering from co-morbidities, remains poorly reported. Finally, the risk factors for serious cases in children remain largely unknown.
This observatory aim to describe the clinical phenotypes of hospitalized pediatric patients with Covid19 in France, according to age groups. Moreover for a subgroup of patients, informations regarding the long covid will be reported.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| hospitalized children with Covid19 | – | Other: hospitalized children with Covid19- Children < 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs |
Who may qualify
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- children hospitalized with covid19
Key inclusion criteria (3 listed)
- Children < 18 years old
- Admitted in French pediatric wards
- With a confirmed COVID-19 infection. ( on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
Key exclusion criteria (1 listed)
- Expressed refusal to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| hospitalized children with Covid19All patients under 18 years hospitalized with a covid19 diagnosis | Other | hospitalized children with Covid19 |
Primary outcome
Percentage of children with severe or critical form.
Time frame: Day 14
13 secondary outcomes
Percentage of children requiring intensive care support
Time frame: at admission
Percentage of children requiring intensive care support
Time frame: at day 14
Clinical symptoms of children
Time frame: at admission
Clinical symptoms of children
Time frame: day 14
Biological results of children
Time frame: at admission
Biological results of children
Time frame: day 14
CT chest of children
Time frame: at admission
Pulmonary echography
Time frame: Day 14
nasopharynx SARScov2 PCR
Time frame: at admission
nasopharynx sarscov2 load
Time frame: at day 7
nasopharynx multiplex PCR
Time frame: at admission
number of hospital days
Time frame: up to 12months
Evaluation of long covid
Time frame: up to 12months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2022.
- Derived from this study: PubMed 39961110Rybak A, Ouldali N, Werner A, Casha P, Robert B, de Pontual L, Bechet S, Cahn-Sellem F, Angoulvant F, Cohen R, Levy C; PANDOR study group. Characteristics of Children Hospitalized for Acute COVID-19 in France From February 2020 to December 2023. Pediatr Infect Dis J. 2025 Apr 1;44(4):346-350. doi: 10.1097/INF.0000000000004681. Epub 2025 Feb 14.
- Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in ChildrenLink provided by the sponsor.
- Factors Associated With Severe SARS-CoV-2 InfectionLink provided by the sponsor.
- Educational Setting and SARS-CoV-2 Transmission Among Children With Multisystem Inflammatory Syndrome: A French National Surveillance SystemLink provided by the sponsor.
- Analysis of COVID-19 Vaccination Status Among Parents of Hospitalized Children Younger Than 5 Years With SARS-CoV-2 Infection During the Delta and Omicron WavesLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for COVID-19
RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2
Active, not recruitingPhase 2
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
Covid19
RecruitingObservational study
Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health
Post-Coronavirus Disease 19
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Enrolling by invitationObservational study
Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic
Dementia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
76 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Centre Hospitalier Intercommunal Creteil at 76 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 76 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Corinne Levy, MD (148850404 ext. 0033, corinne.levy@activ-france.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of children with severe or critical form. (time frame: Day 14). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04336956, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2022.